Promising Clinical Trials for Lung Cancer Treatment
Microbio Co., Ltd. (4128) has recently revealed exciting results from an exploratory clinical trial focused on MS-20, a unique treatment combined with Keytruda for combating stage IIIb/IV non-small cell lung cancer (NSCLC). The trial's findings demonstrate a remarkable threefold increase in the objective response rate (ORR) for patients receiving the combination treatment; 75% of patients responded favorably compared to just 25% with Keytruda alone. Importantly, the median progression-free survival (PFS) for those on MS-20 climbed from 4.5 months to over 12 months, highlighting a significant improvement in patient outcomes.
Enhancing Cancer Immunotherapy Through the Microbiome
Developed by Microbio, MS-20 is a microbiome-based postbiotic. It aims to refine how cancer immunotherapy works by targeting and modulating the gut microbiome. Dr. Wan-Jiun Chen, who serves as the Executive Vice President of Research & Development at Microbio, emphasizes the importance of these results. "These findings support MS-20's capability to reshape the microbiome, possibly boosting the effectiveness of Keytruda in treating advanced NSCLC," he stated. As new therapies emerge in the oncology field, proof-of-concept trials like this one represent exciting steps forward.
Trial Highlights and Patient Outcomes
This randomized, double-blind, placebo-controlled trial included 15 patients, with results analyzed under the modified intent-to-treat (mITT) principle (ClinicalTrials.gov ID: NCT04909034). Out of those receiving both MS-20 and Keytruda, an impressive six patients demonstrated a positive response—culminating in a notable 75% response rate. Among these patients was an individual who maintained a complete response (CR) lasting beyond 22 months and five others who experienced partial responses (PR). In stark contrast, the placebo group saw only one out of four patients achieving a PR, confirming a significant difference in efficacy.
Scientific Understanding and Future Plans
Further support for these findings comes from recent preclinical studies published in Gut Microbes, indicating that MS-20 enhances immune responses by boosting effector CD8 T cells within the tumor microenvironment. With such compelling results, Microbio plans to leverage these findings to expand its collaborations globally and continue developing its microbiome-based cancer immunotherapy technologies.
Introducing Microbio Co., Ltd.
Established in 2000, Microbio Co., Ltd. is dedicated to addressing immune, oncology, and metabolic diseases. Utilizing innovative microbial pharmaceutical technology platforms, the company has created a proprietary library of anaerobic commensal bacteria metabolites. Their research has made significant strides in developing next-generation microbiome-based therapeutics.
Understanding MS-20
MS-20 is notably produced through Microbio's Symbiota™ fermentation process, which leverages multi-strain probiotics in an anaerobic environment. It has been clinically shown to alleviate the side effects of chemotherapy while enhancing the efficacy of immunotherapy treatments. Notably, in 2024, MS-20 achieved an independent self-affirmed GRAS (Generally Recognized As Safe) status in the United States, and it is now being utilized in various food and beverage applications, including specialized medical nutrition products.
Frequently Asked Questions
What is MS-20?
MS-20 is a microbiome-based postbiotic developed by Microbio to enhance cancer immunotherapy by modifying the gut microbiome.
What were the key findings of the recent trial?
The trial showed that MS-20 combined with Keytruda resulted in a 75% response rate, compared to 25% for Keytruda alone, and increased progression-free survival.
Who is Dr. Wan-Jiun Chen?
Dr. Wan-Jiun Chen is the Executive VP of Research & Development at Microbio and has highlighted the significance of MS-20 in enhancing cancer treatment.
What does GRAS status mean for MS-20?
GRAS status indicates that MS-20 is considered safe for consumption based on scientific evidence, enabling its use in various food products.
How does Microbio contribute to cancer treatment?
Microbio focuses on microbiome research and development, aiming to create innovative therapies that improve outcomes for cancer patients and those with metabolic diseases.
